CK19 Antibody KRT19/800 / Cytokeratin 19 Monoclonal Antibody [clone KRT19/800] (V2679)

Description

CK19 Antibody KRT19/800 / Cytokeratin 19 Monoclonal Antibody recognizes keratin 19, a type I intermediate filament protein encoded by the KRT19 gene. Keratin 19 is expressed in many simple and glandular epithelia, where it contributes to the cytoskeletal framework that maintains cellular architecture and tissue integrity. Unlike most type I keratins, KRT19 lacks a conventional C-terminal tail domain. It commonly associates with type II keratins, particularly keratin 8, to form intermediate filament networks that support epithelial cell organization.

CK19 expression is especially prominent in ductal and glandular epithelial compartments. In the hepatobiliary system, cholangiocytes express KRT19, distinguishing them from mature hepatocytes, which generally lack substantial CK19 expression. This distribution makes CK19 Antibody useful for investigating bile duct organization, hepatic progenitor populations, and epithelial remodeling during liver injury. Keratin 19 is also expressed in pancreatic ductal epithelium, bronchial epithelial cells, and portions of the gastrointestinal tract, reflecting its association with specialized epithelial lineages.

During tissue development and regeneration, KRT19 expression can accompany the establishment or maintenance of epithelial identity. In the gastrointestinal system, keratin expression patterns vary along the epithelial differentiation axis and among distinct anatomical regions. Studies of stomach and intestinal epithelia use cytokeratin markers to examine epithelial organization, lineage specification, and responses to tissue damage. CK19 expression may also change during metaplasia and other processes involving altered epithelial differentiation.

In oncology, KRT19 is widely investigated in carcinomas originating from glandular and ductal epithelia. Its expression occurs in numerous epithelial malignancies, including breast, pancreatic, pulmonary, and gastrointestinal carcinomas. Cytokeratin 19 Monoclonal Antibody can support research examining the distribution of CK19-positive tumor populations and their relationship to surrounding tissue structures. However, CK19 expression is not specific to malignancy, and its biological significance depends on tissue context and additional molecular markers.

NSJ Bioreagents provides antibodies targeting KRT19 for research into epithelial differentiation and intermediate filament biology. The reactivity of clone KRT19/800 with human and rat samples supports comparative investigations of epithelial organization across experimental tissue models.

For additional KRT19 detection options, see our anchor Cytokeratin 19 Antibody KRT19/799 | CK19 | V2678.

Application Notes

Optimal dilution of the CK19 Antibody KRT19/800 / Cytokeratin 19 Monoclonal Antibody should be determined by the researcher.

1. Staining of formalin-fixed tissues requires boiling tissue sections in pH 9 10mM Tris with 1mM EDTA for 10-20 min followed by cooling at RT for 20 min
2. The prediluted format is supplied in a dropper bottle and is optimized for use in IHC. After epitope retrieval step (if required), drip mAb solution onto the tissue section and incubate at RT for 30 min.

Immunogen

Recombinant human Cytokeratin 19 protein was used as the immunogen for the CK19 antibody.

Storage

Store the CK19 antibody at 2-8oC (with azide) or aliquot and store at -20oC or colder (without azide).

Alternate Names

Cytokeratin 19 antibody, KRT19 antibody, Keratin 19 antibody, K19 antibody, Type I Cytoskeletal Keratin 19 antibody